THE BE T
Multimedia Highlights
From the CardioSource WorldNews YouTube Channel | Scan the QR code to watch the full video
An ABSORB III PK Substudy:
Checking Systemic Everolimus Levels
from a Bioresorbable Scaffold
Renal Denervation: Down but Not Out?
24-Month Results of IN.PACT SFA
David Kandzari, MD: “You’ll recall that
renal denervation is a procedure that has
no practical biomarker of efficacy. If we
put a stent in a coronary artery blockage,
we can see that we’ve improved that
blockage, but we have no practical measure
[…] of procedural efficacy that we’re really
contributing for renal denervation.”
John R. Laird, MD: “The challenge has
always been infrainguinal interventions
where the results with our endovascular
therapies have never been quite as good
as we’d hoped. The SFA is one of the most
heavily diseased vessels in the body—diffuse
disease is the rule, total occlusions are
common, often the vessels are calcified […]—
all of this negatively impacts the results with
our endovascular therapies.”
Rizik DG, et al. J Am Coll Cardiol.
2015;66(21):2467-9.
Mahfoud F, et al. J Am Coll Cardiol.
2015;66:1766-75.
Laird J, et al. J Am Coll Cardiol.
2015;66(21):2329-38.
Pacemaker Lead Abandonment versus
Lead Extraction: An NCDR® Analysis
Masked Hypertension, White Coat
Hypertension, and Target Organ
Complications
Statins for Primary Prevention:
If We Could Only Predict the Future
David Rizik, MD: “In truth, we probably
only need [a stent] temporarily, for say 3
or 4 months. If you performed a balloon
angioplasty, for instance, we know that the
vessel will recoil for a period of time, and
that’s when you need the stent. After that
period of recoil, however, the stent is no
longer needed.”
Emily P. Zeitler, MD: “Data speaks. There
are some single-center studies and smaller
studies comparing these two strategies, but
there really was no multicenter, high-quality
data to compare outcomes, so we set out to
answer that question.”
Wanpen Vongpatanasin, MD: “Clinicians
should pay more attention not just clinic
blood pressure, but also home blood
pressure, since that obviously could tell
a different story. We have to be careful to
recognize those phenotypes.”
Vera Bittner, MD: “I think that the debate is
going to continue until we have some hard
data. The problem is that we’ll never have
totally airtight data in a primary prevention
population because the trials are incredibly
expensive to do, and there will always be
population groups that fall outside of the trial.”
Tientcheu D, et al. J Am Coll Cardiol.
2015;66:2159-69.
12
CardioSource WorldNews
January 2016